Kei Nakashima1, Masahiro Aoshima2, Tamao Nakashita3, Masahiko Hara4, Ayumu Otsuki2, Satoshi Noma2, Masafumi Misawa2, Yoshihito Otsuka5, Shinji Motojima3. 1. Department of Pulmonary Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan. Electronic address: kei.7.nakashima@gmail.com. 2. Department of Pulmonary Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan. 3. Department of Rheumatology, Kameda Medical Center, Kamogawa, Chiba, Japan. 4. Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. 5. Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan.
Abstract
BACKGROUND/ PURPOSE: The efficacy of low-dose trimethoprim-sulfamethoxazole (TMP-SMX) may be acceptable for the treatment of pneumocystis pneumonia (PCP) in non-human immunodeficiency virus (HIV)-infected patients, with a low incidence of adverse reactions. This study is aimed to evaluate the efficacy and safety of such a regimen for the treatment of non-HIV PCP. METHODS: We retrospectively enrolled 24 consecutive patients diagnosed with non-HIV PCP who were treated with low-dose TMP-SMX (TMP, 4-10 mg/kg/day; SMX, 20-50 mg/kg/day). Data of the conventional-dose treatment were used as reference. The primary endpoints were the 30- and 180-day survival rates from the day of treatment, and secondary endpoints were the incidence of each adverse reaction and dropout rate from the initial TMP-SMX regimen. The survival rate was estimated using the Kaplan-Meier method with 95% confidence interval (CI). RESULTS: The median age of patients was 72 years (54.2% men), and connective tissue disease was the most frequent underlying disease (66.7%) in the low-dose group. The 30- and 180-day survival rates were 95.8% (95% CI: 88.2-100.0%) and 91.0% (95% CI: 79.9%-100.0%), respectively, in the low-dose group and 69.0% (95% CI: 54.0%-88.0%) and 51.5% (95% CI: 36.1%-73.4%), respectively, in the conventional-dose group. The total adverse reaction rate was 58.3% in the low-dose group and 72.4% in the conventional-dose group. A total of 75.0% of patients in the low-dose group and 31.0% in the conventional-dose group completed treatment with the initial regimen. CONCLUSION: Low-dose TMP-SMX may be a treatment option for patients with non-HIV PCP.
BACKGROUND/ PURPOSE: The efficacy of low-dose trimethoprim-sulfamethoxazole (TMP-SMX) may be acceptable for the treatment of pneumocystis pneumonia (PCP) in non-human immunodeficiency virus (HIV)-infectedpatients, with a low incidence of adverse reactions. This study is aimed to evaluate the efficacy and safety of such a regimen for the treatment of non-HIV PCP. METHODS: We retrospectively enrolled 24 consecutive patients diagnosed with non-HIV PCP who were treated with low-dose TMP-SMX (TMP, 4-10 mg/kg/day; SMX, 20-50 mg/kg/day). Data of the conventional-dose treatment were used as reference. The primary endpoints were the 30- and 180-day survival rates from the day of treatment, and secondary endpoints were the incidence of each adverse reaction and dropout rate from the initial TMP-SMX regimen. The survival rate was estimated using the Kaplan-Meier method with 95% confidence interval (CI). RESULTS: The median age of patients was 72 years (54.2% men), and connective tissue disease was the most frequent underlying disease (66.7%) in the low-dose group. The 30- and 180-day survival rates were 95.8% (95% CI: 88.2-100.0%) and 91.0% (95% CI: 79.9%-100.0%), respectively, in the low-dose group and 69.0% (95% CI: 54.0%-88.0%) and 51.5% (95% CI: 36.1%-73.4%), respectively, in the conventional-dose group. The total adverse reaction rate was 58.3% in the low-dose group and 72.4% in the conventional-dose group. A total of 75.0% of patients in the low-dose group and 31.0% in the conventional-dose group completed treatment with the initial regimen. CONCLUSION: Low-dose TMP-SMX may be a treatment option for patients with non-HIV PCP.
Authors: Clayton P Santiago; Casey J Keuthan; Sanford L Boye; Shannon E Boye; Aisha A Imam; John D Ash Journal: Mol Ther Date: 2018-07-19 Impact factor: 11.454
Authors: Hui Peng; Viet Q Chau; Wanida Phetsang; Rebecca M Sebastian; M Rhia L Stone; Shyamtanu Datta; Marian Renwick; Yusuf T Tamer; Erdal Toprak; Andrew Y Koh; Mark A T Blaskovich; John D Hulleman Journal: Mol Ther Methods Clin Dev Date: 2019-08-15 Impact factor: 6.698
Authors: Todd C Lee; Emily G McDonald; Zahra N Sohani; Guillaume Butler-Laporte; Andrew Aw; Sara Belga; Andrea Benedetti; Alex Carignan; Matthew P Cheng; Bryan Coburn; Cecilia T Costiniuk; Nicole Ezer; Dan Gregson; Andrew Johnson; Kosar Khwaja; Alexander Lawandi; Victor Leung; Sylvain Lother; Derek MacFadden; Michaeline McGuinty; Leighanne Parkes; Salman Qureshi; Valerie Roy; Barret Rush; Ilan Schwartz; Miranda So; Ranjani Somayaji; Darrell Tan; Emilie Trinh Journal: BMJ Open Date: 2022-07-21 Impact factor: 3.006
Authors: Guillaume Butler-Laporte; Elizabeth Smyth; Alexandre Amar-Zifkin; Matthew P Cheng; Emily G McDonald; Todd C Lee Journal: Open Forum Infect Dis Date: 2020-04-02 Impact factor: 3.835
Authors: Abdul Haseeb; Mohammed A S Abourehab; Wesam Abdulghani Almalki; Abdulrahman Mohammed Almontashri; Sultan Ahmed Bajawi; Anas Mohammed Aljoaid; Bahni Mohammed Alsahabi; Manal Algethamy; Abdullmoin AlQarni; Muhammad Shahid Iqbal; Alaa Mutlaq; Saleh Alghamdi; Mahmoud E Elrggal; Zikria Saleem; Rozan Mohammad Radwan; Ahmad Jamal Mahrous; Hani Saleh Faidah Journal: Int J Environ Res Public Health Date: 2022-02-28 Impact factor: 3.390